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Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) has been shown to cause G2 cell cycle arrest in
human cells by inducing ATR-mediated inactivation of p34cdc2, but factors directly engaged in this process remain
unknown. We used tandem affinity purification to isolate native Vpr complexes. We found that damaged DNA binding
protein 1 (DDB1), viral protein R binding protein (VPRBP), and cullin 4A (CUL4A)—components of a CUL4A E3 ubiquitin
ligase complex, DDB1-CUL4A
VPRBP—were able to associate with Vpr. Depletion of VPRBP by small interfering RNA
impaired Vpr-mediated induction of G2 arrest. Importantly, VPRBP knockdown alone did not affect normal cell cycle
progression or activation of ATR checkpoints, suggesting that the involvement of VPRBP in G2 arrest was specific to
Vpr. Moreover, leucine/isoleucine-rich domain Vpr mutants impaired in their ability to interact with VPRBP and DDB1
also produced strongly attenuated G2 arrest. In contrast, G2 arrest–defective C-terminal Vpr mutants were found to
maintain their ability to associate with these proteins, suggesting that the interaction of Vpr with the DDB1-VPRBP
complex is necessary but not sufficient to block cell cycle progression. Overall, these results point toward a model in
which Vpr could act as a connector between the DDB1-CUL4A
VPRBP E3 ubiquitin ligase complex and an unknown
cellular factor whose proteolysis or modulation of activity through ubiquitination would activate ATR-mediated
checkpoint signaling and induce G2 arrest.
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Introduction
Human immunodeﬁciency virus type 1 (HIV-1) viral
protein R (Vpr) accessory protein is a small 96 amino acid
protein that plays several roles during virus infection
(reviewed in [1,2]). In particular, the protein mediates cell
cycle arrest at the G2/M transition in various mammalian cells
[3–6], a cytostatic ability that is well conserved among the
primate lentiviruses [7]. Its biological signiﬁcance is not fully
understood but may be related to general activation of virus
expression [8] and/or induction of apoptosis [9]. Vpr
suppresses cell proliferation by preventing the activation of
the p34cdc2/cyclin B complex [3,4]. Accumulating evidence
indicates that Vpr-mediated cell cycle arrest depends on DNA
damage response, but precise mechanisms of its induction
remain obscure.
Phosphatidylinositol 3 kinase like ATM (ataxia telangiec-
tasia mutated) and ATR (ataxia and telangiectasia mutated
and Rad3 related) are key components of the G2/M
checkpoint. In addition, ATR activates S-phase checkpoint
in replication stress response resulting from stalled repli-
cation [10]. Depending on the type of stress, ATR- or ATM-
mediated checkpoints are fully activated by the coordinated
activity of Rad9-Rad1-Hus1 (9-1-1), Rad17-RFC, breast
cancer associated protein (BRCA1), and p53 binding protein
(53BP) (reviewed in [11–13]). ATR- or ATM-dependent
phosphorylation of the histone variant H2AFX (H2AX)
triggers the formation of c-H2AFX/BRCA1 or 53BP foci.
These foci are presumed to help in the recruitment and/or
retention of DNA repair machinery and checkpoint effectors
at the damaged DNA sites, thus promoting checkpoint signal
ampliﬁcation [12]. Downstream activation of CHEK1 or
CHEK2 kinases by ATM and ATR results in the inactivation
of Cdc25 phosphatase and increased expression of both
WEE1 kinase and the 14-3-3 family of proteins. Inactivation
of cdc2/cyclin by hyperphosphorylation and cytoplasmic
retention prevents entry into mitosis before the completion
of DNA repair [10,12].
Several groups have reported that Vpr expression induces
Rad17- and Hus1-dependent activation of ATR, but not of
ATM, and induces the formation of nuclear c-H2AFX/BRCA1
foci [14–16]. However, the mechanism by which Vpr triggers
ATR activation is not well understood. Some authors
proposed that Vpr would interfere with normal DNA
replication, leading to stalled replication forks [15,17], while
others suggested that the protein may promote the formation
of DNA double-strand breaks by recruiting unknown endo-
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Vpr interactions with host chromatin [15,18]. On the other
hand, blockade of the proliferation might rely on the
mislocation of key cell cycle regulators, because of alterations
in the nuclear envelope induced by membrane-anchored Vpr
[19].
To identify Vpr-interacting cellular proteins responsible
for the initial events leading to the induction of G2 arrest, we
used the proteomic tandem afﬁnity puriﬁcation (TAP)
procedure followed by mass spectrometry. Native complexes
containing TAP-Vpr were puriﬁed from human cells by two
consecutive afﬁnity chromatographic steps under mild
conditions. Here, we identify a novel protein complex
comprising Vpr, the damaged DNA binding protein 1
(DDB1), the E3 ubiquitin ligase scaffold protein cullin 4A
(CUL4A), and the newly identiﬁed DDB1-CUL4A–associated
factor 1 (DCAF1), which is also designated as viral protein R
binding protein (VPRBP) [20–22]. We provide functional
evidence indicating that Vpr interaction with this E3
ubiquitin ligase complex is involved in induction of G2 cell
cycle arrest.
Results
Vpr Interacts with DDB1 and VPRBP
To purify cellular protein complexes interacting with HIV
Vpr, Vpr was fused to a TAP tag containing two immuno-
globulin-binding domains of protein A from Staphylococcus
aureus, a cleavage site for the tobacco etch virus (TEV)
protease, and the calmodulin-binding peptide (CBP). Since
Vpr C-terminal modiﬁcations have been reported to alter its
cytostatic abilities [23], the bipartite tag was introduced N-
terminally. Puriﬁcation of TAP-Vpr–containing complexes
was then conducted in human embryonic kidney (HEK) 293T
cells, although the tagged protein induced cell cycle arrest
less efﬁciently than wild-type Vpr (unpublished data). After
electrophoresis and silver staining, two bands corresponding
to high–molecular weight proteins were repeatedly observed
(unpublished data). Matrix-assisted laser desorption/ioniza-
tion time-of-ﬂight mass spectrometric analysis revealed that
the upper band corresponded to VPRBP, a 180-kDa protein
that had been isolated as a Vpr-binding factor a decade ago,
but whose function still remained obscure [21,22]. The other
120-kDa protein was identiﬁed as DDB1, initially considered
part of a heterodimeric complex containing damaged DNA
binding protein 2 (DDB2), involved in a cellular response to
UV-induced DNA damages [24,25]. However, the protein is
now emerging as a central scaffolding factor in the DDB1-
CUL4A-RBX1 E3 ubiquitin ligase complex associated with the
COP9 signalosome [26]. Importantly, recently the WD40
protein VPRBP has been demonstrated to interact with DDB1
and probably serves as an adapter to confer substrate
speciﬁcity to the DDB1-CUL4A-RBX1 E3 ubiquitin ligase
complex [20].
We sought to conﬁrm the interaction of Vpr with DDB1
and VPRBP in HEK293T cells transfected with TAP or TAP-
Vpr expression plasmids. TAP pull-down experiments were
performed on cell lysates using IgG-coated sepharose beads.
Co-precipitated endogenous DDB1 and VPRBP were de-
tected by Western blot using speciﬁc antibodies. As shown in
Figure 1A, endogenous DDB1 and VPRBP could be pulled
down when co-expressed with TAP-Vpr (lane 3), but not when
the protein was in the presence of the native TAP tag (lane 2),
indicating that DDB1 and VPRBP binding was speciﬁc to
TAP-Vpr. These interactions could be detected in conditions
containing 1% NP40 (unpublished data) as well as 0.5%
Triton X-100 (Figure 1A).
To conﬁrm the speciﬁcity of the interaction between Vpr
and DDB1, we performed pull-down assays in cells co-
transfected with TAP-Vpr and hemagglutinin (HA)-tagged
DDB1–encoding plasmids (Figure 1B). We were able to
observe that HA-DDB1 could be co-precipitated speciﬁcally
in the presence of TAP-Vpr (lane 6), but not in the presence
of the empty plasmid (lane 2) or a TAP-expressing plasmid
(lane 5). We constructed TAP-DDB1 as well as green
ﬂuorescent protein (GFP)–tagged DDB1 expression plasmids
to verify whether the interaction could be observed in the
reversed orientation. However, immunoprecipitation using
endogenous, TAP-tagged, HA-tagged, or GFP-fused DDB1 as
bait and wild-type or HA-tagged Vpr yielded inconsistent
results (unpublished data). These discrepancies between HA-
Vpr and TAP-Vpr abilities to bind to DDB1 are reminiscent
of the versatile association between DDB1 and the DNA
replication licensing factor CDT1. In that case, detection of
DDB1-CDT1 complexes in absence of chromatin was depend-
ent on the amount of antibody used for the immunopreci-
pitation [20]. Given that CDT1 interacts indirectly with DDB1
via the adapter protein CDT2 [27,28], it is tempting to
hypothesize that Vpr would likewise interact indirectly with
DDB1 through an adapter protein, perhaps VPRBP, and that
the TAP/IgG bead complexes may somehow stabilize the
interaction.
To conﬁrm the speciﬁcity of interaction between Vpr and
VPRBP in our system, we performed co-immunoprecipitation
experiments in the presence of endogenous VPRBP and over-
expressed HA-Vpr (Figure 1C). We could speciﬁcally detect
co-immunoprecipitated VPRBP in the presence of HA-Vpr
(lane 2), but not in the presence of the empty plasmid (lane 1).
Finally, we observed an interaction between over-expressed
HA-Vpr and Myc-tagged VPRBP (Figure 1D), conﬁrming the
speciﬁcity of the interaction between Vpr and VPRBP.
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Author Summary
Human immunodeficiency virus type 1 (HIV-1), the causative agent
of AIDS, encodes several proteins termed accessory, which play a
critical role in viral pathogenesis. Collectively, HIV-1 accessory
proteins Vif, Vpr, Vpu, and Nef have been shown to manipulate
host cell biology to promote viral replication, immune evasion, and
AIDS progression. In this context, Vpr has been found to block
normal cell growth. This interruption of cell division by Vpr is
thought to increase viral replication and induce programmed cell
death. However, how Vpr is able to block cell division remains
unknown. To understand this mechanism, we have studied the
interaction between Vpr and novel cellular proteins. We identified a
novel complex comprising Vpr and cellular proteins involved in a
process called ubiquitination. Ubiquitination is a mechanism by
which a small protein, ubiquitin, is conjugated to cellular proteins to
modulate their activity or induce their degradation. We demon-
strated that association of Vpr with this ubiquitinating complex
might be responsible for the defect in cell growth. Further
characterization of this protein complex and the elucidation of the
mechanism by which it affects cell growth might lead to the
development of new anti-HIV drugs and an improved under-
standing of the basic cellular processes controlling cell division.DDB1 Appears to Bind to Vpr Indirectly
To further investigate the apparent association between
TAP-Vpr and DDB1, Vpr, TAP, and TAP-Vpr sequences were
subcloned in yeast two-hybrid expression constructs. Saccha-
romyces cerevisae cells were co-transformed with each combi-
nation of plasmids. Interaction afﬁnities were determined by
measurement of the b-galactosidase activity. As expected, Vpr
appeared to form homodimers, leading to strong reporter
gene activity (Figure 2A). Surprisingly, no binding could be
detected between Vpr and DDB1, a result consistent with the
lack of interaction observed with some co-immunoprecipita-
tion experiments. We found that dimerization of TAP-Vpr
was three times weaker than that of the wild-type protein.
Hence, N-terminal addition of large peptide appears to
disturb the tertiary structure of Vpr, explaining at least in
part the reduction of TAP-Vpr cytostatic abilities. Impor-
tantly, we found that b-galactosidase activity remained
undetectable in cells co-expressing TAP-Vpr and DDB1. This
lack of stable interaction between Vpr and DDB1 did not
result from lack of DDB1 expression in yeast, since we could
observe DDB1 expression by Western blot in Vpr-expressing
yeast cells (Figure 2A). Finally, an association between Vpr
and DDB1 could not be detected in co-immunoprecipitation
experiments using in vitro–translated T7-tagged Vpr and
HA-DDB1 proteins (Figure 2B) in conditions that have
demonstrated an association between Vpr and VPRBP [21];
this suggests that the binding observed in human cells might
be indirect and may involve a bridging factor.
Vpr Associates with a DDB1-CUL4A
VPRBP E3 Ubiquitin
Ligase Complex
One possible explanation for the apparent association
between Vpr and DDB1 is that Vpr would associate with the
DDB1-CUL4A-RBX1 ubiquitin ligase complex through a
direct interaction with VPRBP. Indeed, recently the WD40
protein VPRBP has been demonstrated to interact with DDB1
and probably serves as an adapter to confer substrate
speciﬁcity to the DDB1-CUL4A-RBX1 E3 ubiquitin ligase
complex [20].
To assess the possibility that the Vpr-VPRBP-DDB1
complex might be part of an ubiquitin E3 ligase complex,
Figure 1. Immunoprecipitation of DDB1/Vpr and VPRBP/Vpr Complexes
(A) HEK293T cells were mock transfected (lanes 1) or transfected with either TAP (lanes 2) or TAP-Vpr–expressing plasmids (lanes 3). Two days later,
immunoprecipitations of TAP tag were performed on cell lysates using IgG-coupled beads and purified complexes were eluted by cleavage with TEV
protease. The levels of endogenous VPRBP and DDB1 were monitored in crude lysates and pulled-down fractions by Western blot using specific
antibodies. TAP, TAP-Vpr, and cleaved Vpr were detected using a polyclonal rabbit antibody directed against a Vpr N-terminal peptide.
(B) HEK293T cells were mock transfected (lanes 1 and 2) or transfected with either TAP (lanes 3 and 5) or TAP-Vpr–expressing plasmids (lanes 4 and 6).
Cells were transcomplemented with the empty vector (lanes 1, 3, and 4) or HA-DDB1–encoding plasmid (lanes 2, 5, and 6).
(C) HEK293T cells were mock transfected (lanes 1) or transfected with HA-Vpr–expressing plasmid (lanes 2). Immunoprecipitations using anti-HA
antibodies were performed on cell extracts using protein A–sepharose beads. The levels of HA-Vpr and endogenous VPRBP were monitored in cell
extracts as well as immunoprecipitated fractions by Western blot using specific antibodies.
(D) HEK293T cells were mock transfected (lanes 1 and 3) or transfected with a HA-Vpr–expressing plasmid (lanes 2 and 4). Cells were
transcomplemented with the empty vector (lanes 1 and 2) or Myc-VPRBP–encoding plasmid (lanes 3 and 4). Anti-HA immunoprecipitations were
performed as described above.
doi:10.1371/journal.ppat.0030085.g001
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ligase scaffold protein CUL4A. HEK293T cells were trans-
fected with plasmids expressing TAP and TAP-Vpr, and pull-
down assays were performed on cell extracts containing
endogenous CUL4A. These assays demonstrated that endog-
enous CUL4A could speciﬁcally associate with TAP-Vpr but
not with native TAP (Figure 3A, lane 3), suggesting that Vpr
associates with a CUL4A-scaffolded E3 ligase complex.
Moreover, anti-CUL4A immunoprecipitation experiments
on cells transfected with an empty plasmid or an HA-Vpr–
expressing plasmid revealed that HA-Vpr co-immunopreci-
pitated with a CUL4A-containing complex (Figure 3B, lane 2),
conﬁrming that Vpr can associate with an E3 ligase complex
with potential ubiquitinating activities. Importantly, VPRBP
could be co-immunoprecipitated along with CUL4A (Figure
3B). Therefore, given the mutual association of Vpr (Figure
1A, 1C, and 1D therein and [21,22]) and CUL4A (Figure 3B
therein and [20]) with VPRBP, these results suggest that Vpr
interacts with the DDB1-CUL4A
VPRBP E3 ubiquitin ligase in a
single complex and that this association might occur via the
intermediary of VPRBP.
The Interaction between DDB1-CUL4A
VPRBP and Vpr Is
Required for the Induction of G2 Arrest
We next sought to study the potential role of DDB1-
CUL4A
VPRBP E3 ubiquitin ligase in the induction of G2 cell
cycle arrest by Vpr. DDB1 depletion by small interfering RNA
(siRNA) has been reported to induce the accumulation of
cells in G2/M due to DNA re-replication [28]; consequently,
this strategy could not be used to demonstrate the involve-
ment of DDB1-CUL4A
VPRBP in the induction of Vpr-
mediated G2 arrest. As an alternative strategy, we analyzed
the effect of siRNA-mediated VPRBP knockdown on Vpr
cytostatic properties. Cells transfected with VPRBP siRNA
displayed a major reduction of VPRBP at the mRNA level
(Figure 4A) as well as at the protein level (Figure 4B)
compared with scrambled siRNA-transfected cells. We thus
transfected HEK293 cells with siRNA against VPRBP and, 24
h later, transduced these cells with a lentiviral vector co-
expressing GFP and native Vpr. We observed that cells
transfected with VPRBP siRNA displayed strongly attenuated
Vpr-mediated G2 arrest as compared with cells that received
scrambled control siRNA (Figure 5A). This difference in the
induction of G2 arrest was not due to a defect in infectivity
potentially resulting from VPRBP knockdown, because the
levels of transduction were equivalent in all the conditions
tested (unpublished data). To verify that this defect in the
induction of G2 arrest in VPRBP-depleted cells was the result
of the abrogation of the Vpr–VPRBP interaction rather than
a defect in cell growth, we treated these cells with nocodazole
with the rationale that properly cycling cells should accumu-
late in mitosis because of the effect of the drug on
microtubule polymerization (Figure 5B). In response to
nocodazole, cells transfected with VPRBP siRNA alone or
with the concomitant expression of Vpr accumulated at the
G2/M phase, indicating that knockdown of VPRBP speciﬁcally
impaired Vpr-mediated G2 arrest functions. Moreover, the
knockdown of VPRBP did not produce any observable defects
in the activation of the ATR-mediated checkpoints, since
treatment with low concentrations of aphidicolin, a DNA
replication inhibitor known to produce DNA double-strand
breaks at fragile chromosomal sites and to activate the ATR-
mediated intra-S checkpoint [29–31], blocked cell cycle
progression at the S-phase in scrambled as well as VPRBP
siRNA-transfected cells (Figure 5C). Finally, we analyzed the
Figure 2. Absence of Direct Vpr Binding to DDB1 in Yeast
(A) The EGY48 reporter strain containing LexA-TAP, LexA-Vpr, or LexA-TAP-Vpr (‘‘bait’’) was transformed with B42, B42-DDB1, or B42-Vpr–expressing
plasmid (‘‘prey’’). The binding affinity between the different proteins was assessed by assaying b-galactosidase activity using the o-nitrophenyl-b-D-
galactopyranoside method. Histograms represent averaged data from 2–4 different clones and are representative of two independent assays. Western
blot analysis of induced and non-induced B42-HA-DDB1 expression in the B42 and B42-DDB1-transformed EGY48/LexA-Vpr reporter strain is shown
below.
(B) In vitro–translated T7-Vpr was immunoprecipitated with an anti-T7 antibody in the presence or absence of in vitro–translated HA-DDB1. Amounts of
protein initially added to the assay (input) are shown in the left panel. * represents non-specific proteins immunoprecipitated by the anti-T7 antibody.
doi:10.1371/journal.ppat.0030085.g002
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VPRBP to Induce G2 Arrestrole of VPRBP in the induction of G2 arrest by Vpr in the
context of viral infection. SiRNA-transfected cells were
infected with vesicular stomatatis virus glycoprotein G
(VSV-G)–pseudotyped fully infectious isogenic viruses defec-
tive (NL4–3DVpr-GFP, vpr ) or proﬁcient (NL4–3-GFP, vprþ)
for Vpr expression. Cells were analyzed for their cell cycle
proﬁle 48 h after infection. As expected, cells transfected with
scrambled control siRNA accumulated in G2 after infection
with the vprþ but not with the vpr  virus (Figure 5D).
Knockdown of VPRBP almost abrogated the accumulation of
cells in G2 in response to vprþ virus infection, but did not
signiﬁcantly affect the cell cycle proﬁle of vpr virus–infected
cells. Again, these differences in G2 arrest were not the result
of differential infectivity (unpublished data). Overall, these
results indicate that VPRBP is necessary for Vpr-induced G2
arrest, suggesting that the DDB1-CUL4A
VPRBP E3 ligase
complex might be involved in this Vpr biological activity.
To examine whether the association of Vpr to the E3 ligase
complex is required, we tested the ability of several TAP-
tagged Vpr mutants to associate with VPRBP and DDB1
(Figure 6A and 6B) and assessed their effect on Vpr-induced
G2 arrest (Figure 6C). HEK293T cells were transfected with
plasmids expressing mutants of TAP-Vpr, and TAP pull-down
experiments were performed on these transfectant cellular
extracts. As previously observed, TAP-Vpr was able to pull
down endogenous VPRBP and DDB1 (Figure 6A, lane 3).
Interestingly, the classical Vpr mutants S79A and R80A that
are attenuated for the induction of G2 arrest (Figure 6C;
[32,33]) could still associate with VPRBP and DDB1 at levels
comparable with that of the wild-type protein (Figure 6A,
compare lane 3 with lanes 5 and 6), suggesting that the
association between Vpr and the DDB1-VPRBP complex, per
se, is not sufﬁcient to block cell cycle progression. Moreover,
W54R, a mutant of Vpr that was previously shown to be
defective for the interaction and degradation of uracil-DNA
glycosylase (UNG2/CCNU) [34], was still capable of associating
with the DDB1-CUL4A
VPRBPcomplex (Figure 6A, lane 4) and
mediating G2 arrest (Figure 6C), suggesting that UNG2 and
VPRBP bind to two distinct domains on Vpr. Zhao et al.
previously mapped the domain of interaction of VPRBP to
the leucine/isoleucine–rich domain of Vpr [22]. We analyzed
whether the L64A and Q65R mutations in this domain of Vpr
could abrogate binding to VPRBP. Using our TAP-Vpr pull-
down assay, we observed a very strong reduction of binding to
Figure 3. Vpr Associates with the Ubiquitin Ligase Scaffold Protein CUL4A
(A) Five million HEK293T cells were transfected with 40 lg of empty (lanes 1), TAP-expressing (lanes 2), or TAP-Vpr–expressing plasmids (lanes 3). Forty-
eight hours after transfection, TAP pull-downs were performed on cell lysates using IgG-coupled beads, and purified complexes were eluted by
cleavage with TEV protease. The levels of endogenous CUL4A were monitored in crude lysates and pulled-down fractions by Western blot using a
polyclonal goat anti-CUL4A antibody. TAP, TAP-Vpr, and cleaved Vpr were detected using a polyclonal rabbit antibody directed against a Vpr N-terminal
peptide.
(B) Ten million HEK293T cells were transfected with 80 lg of empty plasmid (lanes 1) or with HA-Vpr–expressing plasmid (lanes 2). Immunoprecipitation
of endogenous CUL4A was performed using a goat polyclonal anti-CUL4A antibody and protein A–sepharose beads. The levels of endogenous CUL4A,
VPRBP, and over-expressed HA-Vpr were monitored in crude lysates and immunoprecipitated fractions by Western blot using, respectively, a polyclonal
goat anti-CUL4A antibody, a polyclonal rabbit anti-VPRBP antibody, and a monoclonal mouse anti-HA antibody.
* represents a non-specific protein detected by the anti-CUL4A antibody. The anti-CUL4A antibody generally recognized a doublet of CUL4A when the
gel resolution was sufficiently high. In the TAP pull-down fractions, only the upper band of CUL4A was detected.
doi:10.1371/journal.ppat.0030085.g003
Figure 4. Depletion of VPRBP Using siRNA
HEK293 cells were transfected with 300 pmol of VPRBP-targeting siRNA or control scrambled siRNA using Oligofectamine.
(A) At 24, 48, and 72 h post-transfection, RNA was extracted and analyzed by RT-PCR to determine the extent of VPRBP downregulation at the mRNA
level. PCR products were analyzed in the exponential phase of amplification. Actin levels were used as a control for RNA quality and reverse
transcription efficiency.
(B) Forty-eight hours after siRNA transfection, cells lysates were harvested and analyzed by Western blot using a polyclonal rabbit anti-VPRBP antibody
to demonstrate the downregulation of VPRBP at the protein level. Actin levels were used as a control for protein loading.
doi:10.1371/journal.ppat.0030085.g004
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VPRBP to Induce G2 ArrestVPRBP and DDB1 with the Q65R mutant (under longer
exposure VPRBP could be detected) (Figure 6B, compare
lanes 3 and 4). A residual association with DDB1 was observed
under these conditions, most likely reﬂecting difference in
antibody afﬁnities. Additionally, the reduction of TAP-Vpr
binding to VPRBP and DDB1 could be observed with the
L64A mutant, though it was less pronounced (Figure 6B,
compare lanes 5 and 6). Interestingly, with both mutants, the
reduced afﬁnity for VPRBP was accompanied by a concom-
itant decrease in the association with DDB1, again suggesting
that VPRBP and DDB1 are likely to form a single complex
with Vpr (Figure 6B, compare lane 3 with lane 4 and lane 5
with lane 6). Importantly, we found that Vpr (L64A) and Vpr
(Q65R) were strongly attenuated for the induction of G2
arrest (Figure 6C). Indeed, the residual level of G2 arrest
observed with these two mutants was comparable with the
attenuated G2 arrest produced by the R80A mutation.
Together, these results suggest that the interaction of Vpr
with the DDB1-CUL4A
VPRBP E3 ubiquitin ligase complex is
necessary but not sufﬁcient to induce G2 arrest.
Discussion
The induction of G2 arrest by the HIV-1 accessory protein
Vpr was described more than ten years ago [3–6]; however,
the mechanism by which Vpr can accomplish this function
has remained elusive. Several recent reports have demon-
strated that expression of Vpr leads to activation of ATR, as
well as to the formation of DNA repair foci containing
BRCA1 and c-H2AFX [14–16]. Nonetheless, the initial events
leading to ATR checkpoint signaling are not known. Herein,
we have used the TAP method to isolate cellular protein
complexes interacting with HIV-1 Vpr to identify cellular
factors that would be involved in Vpr-mediated ATR
activation and subsequent G2 arrest. Using this strategy, we
have identiﬁed DDB1 and VPRBP as cellular factors forming
a complex with Vpr.
DDB1 is part of the DDB1-CUL4A-RBX1 E3 ubiquitin
ligase complex that targets proteins for degradation via the
COP9 signalosome [26]. In this complex, DDB1 serves as a
scaffold protein presenting substrate to the E3 ubiquitin
ligase. The protein is structurally complex and contains three
seven-bladed b propellers (bPA, bPB, and bPC) [35]. The bPB
propeller is involved in the interaction with CUL4A, whereas
the bPA–bPC double-propeller fold is responsible for
substrate presentation via interaction with WD40-repeat
proteins [35]. Over 15 different WD40-containing substrate
receptors, including DDB2, CSA, DET1-COP1, and CDT2,
have been shown to interact with DDB1 and are thought to
confer substrate speciﬁcity [20,35–37]. However, to date, only
a few cellular proteins have been found to be regulated by the
DDB1-CUL4A-RBX1 complex. In human cells, DDB1-CU-
L4A
DDB2 promotes the ubiquitylation of histone 2A [38],
histone 3, histone 4 [39], and the xeroderma pigmentosum
group C protein (XPC) to regulate their activity [40]. In
contrast, DDB1-CUL4A
CSA and DDB1-CUL4A
DET1-COP1 pro-
mote proteolysis of Cockayne syndrome type B gene product
(CSB) [26] and c-JUN [41]. Recently, DDB1, via the WD40
adapter CDT2, has been shown to prevent DNA re-repli-
cation during normal S-phase progression or in response to
S-phase accumulation of DNA lesions by regulating the
degradation of the replication licensing factor CDT1 [27,28].
Interestingly, DDB1 also forms complexes with two other
viral proteins, namely hepatitis B virus X protein [42–44] and
simian paramyxovirus SV5 V protein [45,46]. Whereas the
mechanisms underlying the DDB1-dependent cytotoxicity
induced by hepatitis B virus X protein remain poorly
understood, it has been established that SV5 V protein
facilitates the ubiquitination and subsequent signalosome-
mediated degradation of STAT1 [45]. Several data argue in
favor of a functional involvement of DDB1-CUL4A-RBX1 in
Vpr functions. CUL4A has been implicated in Vpr-induced
degradation of UNG2 and SMUG1 proteins [47], and Vpr was
shown to interact with VIP/mov34/CNS6, one of the subunits
of CUL4A-associated signalosome [48].
In our system, an interaction between Vpr and DDB1 was
observed when Vpr was fused to a TAP tag (TAP experiments,
Figure 1A and 1B). However, co-precipitations in the reverse
direction with DDB1 fused to other tags (TAP, HA, or GFP)
only yielded inconsistent interaction results (unpublished
data). The lack of apparent interaction between DDB1 and
Vpr in that context may be due to our experimental
conditions or to the type of association that engages Vpr
and DDB1. In that regard, the lack of interaction between
Vpr and DDB1 in the yeast two-hybrid system (Figure 2A) as
well as in in vitro co-precipitation experiments (Figure 2B)
argued for an indirect interaction between these two
proteins, though deﬁnite demonstration of this will require
a more thorough analysis of this association in the future.
These results were in contrast to SV5 V protein, which can
directly interact with the DDB1 bPA–bPC domain [35,49].
Through the use of TAP procedures (unpublished data),
immunoprecipitation experiments (Figure 1), and several Vpr
mutants (Figure 6), we identiﬁed VPRBP as a cellular factor
also in a complex with Vpr and DDB1 that possibly permits
the recruitment of a DDB1-CUL4A E3 ubiquitin ligase
complex. The cellular function of VPRBP has recently been
uncovered through different proteomic approaches. It is a
WD40 protein linked to the DDB1-CUL4A-RBX1 complex
and probably serves as an adapter presenting protein
Figure 5. Effect of VPRBP Depletion on Vpr-Induced G2 Arrest
(A) HEK293 cells were transfected with 300 pmol of VPRBP-targeting siRNA or control scrambled siRNA using Oligofectamine, followed by the same
transfection 24 h later. Twenty-four hours after the second siRNA transfection, cells were transduced at a multiplicity of infection of 1 with lentiviral
vectors expressing Vpr (WPI-Vpr) or the empty vector (WPI). Cell cycle profiles were analyzed 24 h after transduction by flow cytometry using propidium
iodide staining.
(B and C) To determine if cell growth (B) or checkpoint activation (C) was affected by VPRBP knockdown, HEK293 cells were transfected once with siRNA,
as described above, and treated respectively with 1 lg/ml nocodazole and 0.5 lM aphidicolin 24 h later. Cell cycle profiles were analyzed 24 h after drug
treatment.
(D) To determine if VPRBP knockdown could also abrogate the induction of G2 arrest in the context of viral infection, siRNA-transfected cells were
infected with NL4.3-GFP and NL4–3DVpr-GFP at a concentration of 100 cpm/cell and cell cycle profiles were analyzed 48 h later.
Percentages of G1 and G2/M cell populations were determined using the ModFit software. These results are representative of the data obtained in at
least two independent experiments.
doi:10.1371/journal.ppat.0030085.g005
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ortholog has been identiﬁed in yeast [21], perhaps explaining
why we did not observe an interaction between Vpr and
human DDB1 in S. cerevisae (Figure 2A) and why the DDB1
ortholog was not found among the putative Vpr-interacting
proteins isolated by TAP assay in Schizosaccharomyces pombe
(unpublished data).
To further characterize the possibility that Vpr might
interact with a DDB1-CUL4A
VPRBP E3 ligase complex, we
investigated whether the scaffold protein CUL4A could
associate with Vpr. Interestingly, we could demonstrate the
formation of a complex containing Vpr and CUL4A using
two different approaches: by TAP-Vpr pull-down (Figure 3A)
and by anti-CUL4A immunoprecipitation (Figure 3B). There-
fore, it appears that Vpr can indeed recruit an E3 ligase
complex with potential ubiquitinating activity. In these
experiments, VPRBP was found in respective association
with Vpr (TAP experiments, Figure 1A, 1C, and 1D), as well as
with CUL4A (Figure 3B). Considering these interaction
results and previous reports demonstrating the association
Figure 6. DDB1 and VPRBP Binding Affinities of TAP-Tagged Vpr Mutants
(A) HEK293T cells were transfected with TAP-Vpr plasmids encoding for wild-type Vpr (lanes 3) or Vpr mutants W54R (lanes 4), S79A (lanes 5), and R80A
(lanes 6). As control, cells were mock transfected (lanes 1) or transfected with a TAP-expressing plasmid (lanes 2). Following TAP pull-down using IgG-
coupled beads, the levels of endogenous VPRBP and DDB1 were monitored in crude lysates and pulled-down fractions by Western blot using specific
antibodies. TAP, TAP-Vpr, and cleaved Vpr were detected using a polyclonal rabbit antibody directed against a Vpr N-terminal peptide.
(B) HEK293T cells were transfected with TAP-Vpr plasmids encoding for wild-type Bru Vpr (lanes 3) and wild-type NL4–3 Vpr (lanes 5), or Vpr mutants
Bru Q65R (lanes 4) and NL4–3 L64A (lanes 6). As control, cells were mock transfected (lanes 1) or transfected with a TAP-expressing plasmid (lanes 2).
TAP pull-downs and immunodetection of VPRBP, DDB1, TAP, and Vpr were performed as described for (A).
(C) HEK293T cells were co-transfected with 1 lg of GFP-expressing plasmid and 15 lg of TAP-Vpr plasmids expressing wild-type or mutant proteins. Cell
cycle analysis was performed using propidium iodide staining on the GFPþ cell population as described in Materials and Methods. Percentages of G1
and G2/M cell populations were determined using the ModFit software.
doi:10.1371/journal.ppat.0030085.g006
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between CUL4A and VPRBP [20], it is most likely that Vpr
interacts with the DDB1-CUL4A E3 ligase complex via the
intermediary of VPRBP, although direct proof will require
further analysis of the protein complex architecture.
Importantly, we observed that not only VPRBP but also the
formation of a Vpr-DDB1-CUL4A
VPRBP complex was re-
quired for Vpr-mediated induction of G2 arrest. Indeed,
siRNA targeting VPRBP strongly impaired the induction of
G2 arrest in the context of a lentiviral vector expressing Vpr
and of a fully infectious provirus (Figure 5A and 5D).
Knockdown of VPRBP did not produce cell cycle aberrations
(Figure 5B and 5C) or reduce viral/vector infection efﬁciency,
suggesting that the observed defect in G2 arrest was speciﬁc
to the association of Vpr with VPRBP.
It has been extensively shown that Vpr C-terminal residues
78 96 are important for G2 arrest [23,50–52], but we found
that TAP-tagged Vpr mutants S79A and R80A attenuated for
cell cycle arrest were nevertheless competent for association
with DDB1 (Figure 6). This was not surprising given that Zhao
et al. showed that VPRBP binding required the leucine/
isoleucine-rich domain of Vpr [22]. In fact, L64A and Q65R,
two mutations in the leucine/isoleucine-rich domain, reduced
to different extents the binding of Vpr to VPRBP (Figure 6B).
We also observed a concomitant decrease of afﬁnity between
Vpr and DDB1 as a result of these mutations, suggesting that
a single complex comprised of VPRBP and DDB1 is binding
to the leucine/isoleucine-rich domain of Vpr. Importantly,
these two mutations strongly attenuated Vpr-induced G2
arrest (Figure 6C). Overall, these results suggest that recruit-
ment of DDB1-CUL4A
VPRBP by Vpr is necessary but not
sufﬁcient to induce G2 cell cycle arrest.
One possible model to explain how Vpr induces G2 arrest
via the DDB1-CUL4A
VPRBP complex is that Vpr could cause a
generalized defect in the activity of the whole DDB1 complex.
In this context, other investigators have shown that abroga-
tion of DDB1 function using siRNA resulted in the failure to
degrade CDT1, thus leading to the accumulation of re-
replicated DNA fragment and the induction of an ATR-
dependent G2 arrest [28]. Therefore, Vpr, through a potential
sequestration of DDB1, might be capable of inducing the
defective regulation of CDT1 or other DDB1-CUL4A E3
ligase complex substrates leading to ATR-mediated G2 arrest.
However, we did not observe any obvious effect of Vpr on the
S-phase degradation of CDT1 (unpublished data), which
suggests that the DDB1-CUL4A-RBX1 complex was fully
functional. Another possible model is that Vpr could block
the proper ubiquitination of natural substrates of DDB1-
CUL4A
VPRBP, thereby affecting their biological activities or
preventing their degradation. However, this possibility is
unlikely because siRNA-mediated knockdown of VPRBP did
not produce G2 arrest (Figure 5). The most probable model is
that Vpr triggers the degradation of a yet-unknown modu-
lator of cell cycle progression by targeting it to the substrate
receptor VPRBP, itself linked to the DDB1-CUL4A-RBX1 E3
ligase complex. This situation would be highly similar to the
mechanism by which Vpu induces the degradation of CD4 by
recruiting directly CD4 to the SCF
b-TRCP E3 ubiquitin ligase
complex [53]. However, we cannot exclude the possibility that
the Vpr–VPRBP interaction might modulate the activity of
substrates through ubiquitination, as was described for XPC
and histones [38–40]. Therefore, the formation of a complex
between Vpr and DDB1-CUL4A
VPRBP through the Vpr
leucine/isoleucine-rich domain could permit the hypothetical
interaction of Vpr through its C-terminal domain with other
cellular factors whose ubiquitination would induce the initial
events leading to cell cycle arrest. This model is consistent
with recent reports [54,55] demonstrating the involvement of
VPRBP and DDB1 in Vpr-induced G2 cell cycle arrest.
In conclusion, we presented biochemical and functional
evidence suggesting that Vpr is likely the third protein
encoded by HIV-1, besides Vif and Vpu, to interact with the
ubiquitination machinery. Vpr was found to associate with
DDB1 and CUL4A, which are components of the DDB1-
CUL4A-RBX1 E3 ligase complex, possibly through the
intermediary of the WD40 substrate receptor VPRBP.
Importantly, the interaction between Vpr and the VPRBP-
DDB1 complex was shown to be required for the induction of
G2 arrest. Vpr could act as a connector, bridging the DDB1-
CUL4A
VPRBP E3 ubiquitin ligase to an unknown cellular
factor whose proteolysis or modulation of activity through
ubiquitination would activate ATR-mediated checkpoint
signaling and cause G2 arrest.
Materials and Methods
Cells and antibodies. HEK293 and HEK293T cells were maintained
as described elsewhere [56]. The anti-HA tag and anti-Myc tag
monoclonal antibodies were clones 12CA5 and 9E10, respectively.
Rabbit polyclonal antibody against VPRBP was distributed by
Accurate Chemical and Scientiﬁc Corporation (http://www.
accuratechemical.com/). The mouse monoclonal antibody against
DDB1 was obtained from BD Biosciences (http://www.bdbiosciences.
com/). The goat polyclonal antibody against CUL4A was obtained
from Santa Cruz Biotechnology (http://www.scbt.com/). Vpr was
detected using a rabbit polyclonal antibody directed against a Vpr
N-terminal peptide [57].
Plasmid constructions. For the construction of mammalian
expression plasmid psvCMV-TAP, N-terminal TAP tag was ﬁrst PCR
ampliﬁed from the pBS1479 plasmid [58] using primers 59-TCTA-
GACATATGGCAGGCCTTGCGCAAC-39 and 59-GGATCCTCAC-
TACTCGAA-TCGTCATCATCAAGTGCC-39, the last one containing
two stop codons between the XhoI and BamHI restriction sites. The
XbaI/BamHI-digested PCR fragment was then inserted into psvCMV
plasmid [56] linearized with XbaI/BglII. For the construction of the
psvCMV-TAP-Vpr expression plasmid, wild-type and mutant Vpr
genes were PCR-ampliﬁed from the respective psvCMV-HA.Vpr
plasmids [56] using oligonucleotides 59-CTCGAGATGGAA-
CAAGCCCCAG-39 and 59-GGATCCCTAGGATCTACTGGCT-39.
XhoI/BamHI Vpr fragments were ﬁnally fused to the XbaI/XhoI
TAP sequence within psvCMV by 3-fragment ligation. Mammalian
expression plasmids pSRAS-3HADDB1 and pSRAS-GFP.DDB1 [44]
were kindly provided by M. Strubin (University of Geneva, Geneva,
Switzerland). The TAP-DDB1 expression plasmid was constructed by
inserting the XbaI/XhoI TAP fragment in Xba/SalI linearized pSRAS-
3HA.DDB1 plasmid. The Myc-VPRBP expression plasmid was
constructed by PCR ampliﬁcation of the VPRBP cDNA from Image
clone ID 5547856 (American Type Culture Collection, http://www.
atcc.org/). The resulting PCR product was then subcloned in pCMV-
Myc (Clontech, http://www.clontech.com/) at the SalI and NotI sites.
For the construction of the yeast expression plasmids, TAP and TAP-
Vpr sequences were subcloned after PCR ampliﬁcation in the BamHI
sites within pEG202. The DDB1 sequence was extracted from pSRAS-
3HADDB1 by SalI/NotI digestion and introduced in pJG4–5. Vpr-
expressing pJG4–5 and pEG202 plasmids have been described
previously [59].
The second-generation self-inactivating lentiviral vectors pWPI
and pWPXL, as well as the packaging plasmid psPAX2 were
obtained from D. Trono (School of Life Sciences, Swiss Federal
Institute of Technology, Lausanne, Switzerland). A lentiviral vector
tranducing Vpr and GFP (pWPI-Vpr) was generated from pWPI.
Vpr was PCR-ampliﬁed from psvCMV-Vpr [56], using primers
59AAGGATCCATGGAACAAGCCCCAGAAGACC-39 and 59-TAC-
GACTAGTCTAGGATCTACTGGCTCCATTT-39, which contain a
BamHI site at the 59 end and a SpeI site at the 39 end, respectively.
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pWPXL linearized at the same sites. A fragment containing the Vpr-
coding sequence and the EF1-alpha promoter was excised with SpeI
(Klenow-treated) and NotI and then ligated into pWPI at the PmeI
and NotI sites to yield pWPI-Vpr.
Tandem afﬁnity puriﬁcation. Puriﬁcation was done according to
previously published procedures [58]. Brieﬂy, HEK293T cells were
seeded onto ﬁve to ten 150 mm-diameter plates. The next day, cells
were transfected with 10 lg of psvCMV TAP-Vpr plasmid. Cells were
collected 48 h later, washed, and lysed in IPP150 buffer (10 mM Tris-
Cl [pH 8.0], 150 mM NaCl, 0.1% NP40) supplemented with EDTA-free
complete protease inhibitors (Roche Diagnostics Canada, http://www.
rochediagnostics.ca/). Cell debris was removed by low-speed centri-
fugation, and cleared supernatants were loaded onto IgG sepharose
columns (Amersham BioSciences Canada, http://www.gelifesciences.
com/). After extensive washes with IPP150 buffer and a ﬁnal wash with
TEV cleavage buffer (10 mM Tris-Cl [pH 8.0], 150 mM NaCl, 0.1%
NP40, 0.5 mM EDTA, 1 mM DTT), TAP-containing complexes were
eluted by overnight digestion using 100 units of TEV protease
(Invitrogen Canada, http://www.invitrogen.com/) diluted in 1 ml of
TEV buffer. Columns were eluted and washed with 3 ml of IPP150-
calmodulin buffer (10 mM b-mercaptoethanol, 10 mM Tris-Cl [pH
8.0], 150 mM NaCl, 1 mM Mg-acetate, 1 mM imidazole, 2 mM CaCl2,
0.1% NP40) supplemented with 3 ml of 1 M CaCl2 and EDTA-free
complete protease inhibitors. Fractions were passed through calm-
odulin columns (Stratagene, http://www.stratagene.com/), washed in
IPP150 buffer, and ﬁnally eluted with a minimal volume of IPP150
elution buffer (10 mM b-mercaptoethanol, 10 mM Tris-Cl [pH 8.0],
150 mM NaCl, 1 mM Mg-acetate, 1 mM imidazole, 2 mM EGTA, 0.1%
NP40). Recovered proteins were resolved by denaturing 12.5% SDS-
PAGE. Bands detected after silver staining were cut and sent to
Taplin Biological Mass Spectrometry Facility (Harvard Medical
School, Boston, Massachusetts, United States) for MALDI-TOF.
Transfection and immunoprecipitation. Cells were transfected
using the calcium phosphate precipitation method. Cells were
harvested 2 d later, washed, and lysed in Triton lysis buffer (50 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 0.5% Triton X-100, and EDTA-free
complete protease inhibitors). TAP pull-down assays were performed
using 10 ll of IgG-coupled beads. After extensive washes in Triton
lysis buffer, beads were resuspended in 100 ll of TEV cleavage buffer
with 2 units of TEV and incubated for 16 h at 4 8C. Cleaved proteins
were diluted in Laemmli buffer, heat-denatured, and loaded onto
12.5% acrylamide gels for SDS-PAGE. After protein transfer onto
Hybond-ECL membrane (Amersham BioSciences Canada), proteins
were detected by Western blot using speciﬁc antibodies. Immuno-
precipitation experiments were performed on cell extracts lysed in
the Triton lysis buffer as described previously [60].
In vitro translation. T7-Vpr and HA-DDB1 were in vitro translated
using the Active Pro In Vitro Translation kit (Ambion, http://www.
ambion.com/) according to manufacturer instructions.
Cell cycle analyses. Cell cycle analysis of HEK293 cells transduced
by lentiviral vectors was performed as previously described in [56].
The mathematical model MODFIT was used to calculate the
proportions of cells in the G2/M phases and G1 phase of the cell
cycle. For analysis of cell cycle proﬁle in the context of TAP-Vpr,
HEK293T cells were co-transfected with 1 lg of a GFP-expressing
plasmid and 15 lg of TAP-Vpr–expressing plasmids. Forty-eight
hours after transfection, cells were ﬁxed with 1% paraformaldehyde
for 15 min followed by ﬁxation/permabilization with 70% ethanol for
10 min. The rest of the procedure was as described previously [56]
except that ﬂow cytometry analysis was performed on the GFP-
positive cell population.
Yeast two-hybrid assay. The yeast ‘‘bait’’ strains were made by
transforming the EGY48 yeast strain with a URA3 lacZ (b-
galactosidase) reporter plasmid and the different bait plasmids
(expressing the HIS3 gene) by the lithium acetate method. The yeast
‘‘bait’’ strains harboring the bait and reporter plasmids were
transformed with different prey plasmids and selected for the
tryptophan autotrophy phenotype (in addition to the His and Ura
nutritional markers for the bait and LacZ reporter plasmids,
respectively). Determination of the respective interactions was
performed as previously described [59].
Lentiviral vector production, titration, and transduction. VSV-G–
pseudotyped viral particles were produced by transient transfection
of 40 lg of vector (pWPI or pWPI-Vpr), 30 lg of the packaging
construct psPAX2, and 12 lg of the VSV-G–expressing plasmid
psvCMV-IN-VSV-G in ﬁve million HEK293T cells using the calcium
phosphate precipitation method. The vector-containing supernatant
was harvested 48 and 72 h post-transfection, 0.45 lm–ﬁltered, and
concentrated by ultracentrifugation on a sucrose cushion. Concen-
trated vectors were resuspended in culture medium and stored at 80
8C. Vectors were titered as described previously with some
modiﬁcations [61]. Brieﬂy, 5 3 10
4 HEK293T cells were transduced
with serial dilutions of the vector preparations in absence of
polybrene. Twenty-four hours later, cells were ﬁxed with 2% PFA
for 30 min and the percentage of GFP-expressing cells was
determined by ﬂow cytometry. The vector titer was calculated as
the number of transduction units in the linear range of transduction
(5%–10% of GFP-positive cells). For transduction experiments, 1 3
10
5 HEK293 cells seeded in the wells of a 6-well plate were incubated
for 24 h with WPI or WPI-Vpr vectors (at a multiplicity of infection of
1) in presence of 8 lg/ml polybrene, typically achieving a trans-
duction efﬁciency of 90%–95%. Cells were harvested after 24 h for
ﬂow cytometry analysis of cell cycle proﬁling and GFP expression.
Viral clones and infection. The infectious molecular clones
pNL4.3-GFP and pNL4–3DVpr-GFP were obtained from Juan Lama
(Department of Medicine, University of California San Diego, La
Jolla, California, United States) and described in [62]. Virus was
produced by transfecting 5 3 10
6 HEK293T cells with 40 lgo f
proviral DNA and 10 lg of the VSV-G–expressing plasmid psvCMV-
IN-VSV-G as described previously [56]. Virus-containing supernatant
was titered by a standard RT assay as previously described [56].
Virions, at a concentration of 100 cpm/cell, were used to infect
HEK293 cells in 1 ml of culture medium, in absence of polybrene.
Forty-eight hours after infection, cells were harvested for ﬂow
cytometry analysis of cell cycle proﬁling and GFP expression.
siRNA-mediated protein knockdown. siRNA targeting VPRBP
(siGenome SMARTpool M-021119–00) and scrambled control siRNA
(non-targeting siRNA #2) were obtained from Dharmacon (http://
www.dharmacon.com/). siRNA was transfected using Oligofectamine
(Invitrogen Canada) according to the manufacturer instructions.
Brieﬂy, 300 pmol of siRNA were pre-incubated with 15 llo f
Oligofectamine and overlayed on cells at 50% conﬂuence (the ﬁnal
concentration of siRNA was 125 nM). Cells were transduced with
lentiviral vectors 24 h after transfection. In some experiments, cells
were subjected to two sequential transfections of 300 pmol of siRNA,
24 h apart.
Reverse transcriptase polymerase chain reaction (RT-PCR). RNA
was extracted from siRNA-transfected cells at the given time using
the Qiagen RNeasy kit (Qiagen, http://www.qiagen.com/) according to
the manufacturer instructions. After elution, RNA was stored at  80
8C. All reagents for RT-PCR were purchased from Invitrogen Canada.
RNA was reverse transcribed into cDNA using 500 ng of RNA, which
in a ﬁnal volume of 12 ll supplemented with 1 ll of oligo (dT)12–18
(500 lg/ml) and 1 ll of 10 mM dNTP mix, were incubated at 65 8C for
5 min. The mixture was cooled on ice and supplemented with 50 mM
Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 2 units/ll
RNaseOUT Recombinant Ribonuclease Inhibitor (Invitrogen Cana-
da), and 10 units/ll M-MLV RT. Finally, the reverse transcription
reaction mixture was incubated at 37 8C for 50 min and heat-
inactivated at 70 8C for 15 min. One microliter of the reverse
transcription reaction was subsequently used for PCR ampliﬁcation
of b-actin and VPRBP sequences. Brieﬂy, the PCR ampliﬁcation mix
was composed of 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM
MgCl2,5 0lM dNTPs, 1 lM sense and antisense primers, and 0.05
units/ll Taq DNA polymerase. Primers 59-GCTCGTCGTCGA-
CAACGG-CTC-39 and 59-CAAACATGATCTGGGTCATCTTCTC-39
were used for b-actin ampliﬁcation and primers 59-AGGCCATCCA-
CAAGTTTGAC-39 and 59-TCATCTGCCTGCAACATAGC-39 were
used for VPRBP ampliﬁcation. The PCR ampliﬁcation conditions
for VPRBP were as follows: 94 8C for 2 min; 25 cycles of (94 8C for 45
sec; 57 8C for 30 sec; 72 8C for 1 min); 72 8C for 5 min. The conditions
of ampliﬁcation for b-actin were the same except that 18 cycles of
ampliﬁcation were used.
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